AI
Saturday, September 20, 2025 2:16:02 PM
suit,
“What do they have to their name?” 😶
Fact ✅: There was a time in recent history when NWBO had only ONE asset…
Today, NWBO has FIVE+ asset categories. Shorts are finding their position more & more precarious with each step of progress.. that’s why we see the fud flood here 24/7
NWBO’s Assets Include:
⭐️ DCVax®-L & DCVax®-Direct
⭐️ Roswell DC platform(s)
⭐️ Flaskworks Eden technology
⭐️ In-licensed TLR agonist
⭐️ Fully licensed & operational in-house CDMO
NWBO also has some important approvals…
Fact ✅:
The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.
Mar 2023, NWBO & Advent MIA Approval
Aug 2022, NWBO PIP Approval
Dec 2021, NWBO & Advent GMP License Approval
Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…
COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.
⭐️Combo is King!⭐️
⭐️ Lifetime Achievement Award in Medicine, Dr. Liau
⭐️ AACR Advances in Ovarian Cancer Research
⭐️ NWBO to Acquire Advent BioServices
⭐️ Recent Conference
⭐️ DCVax-L Combo PII UCLA
⭐️ DC Combo PII Roswell Park
⭐️ 10-Q Quarterly Report
⭐️ 10-K Annual Report
⭐️ NICE UK 🇬🇧 DCVax-L
⭐️ ASM June 29, 2024
⭐️ Manufacturing Technology
⭐️ NWBO Acquires Flaskworks
⭐️ Roswell Park IP Portfolio
⭐️ TLR3 agonist Ampligen (rintatolimod)
⭐️ Next Generation Dendritic Cell Treatments
⭐️Combo is King!⭐️
AI Fact-Checking
“What do they have to their name?” 😶
Fact ✅: There was a time in recent history when NWBO had only ONE asset…
Today, NWBO has FIVE+ asset categories. Shorts are finding their position more & more precarious with each step of progress.. that’s why we see the fud flood here 24/7
NWBO’s Assets Include:
⭐️ DCVax®-L & DCVax®-Direct
⭐️ Roswell DC platform(s)
⭐️ Flaskworks Eden technology
⭐️ In-licensed TLR agonist
⭐️ Fully licensed & operational in-house CDMO
NWBO also has some important approvals…
Fact ✅:
The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.
Mar 2023, NWBO & Advent MIA Approval
Aug 2022, NWBO PIP Approval
Dec 2021, NWBO & Advent GMP License Approval
Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…
COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.
⭐️Combo is King!⭐️
⭐️ Lifetime Achievement Award in Medicine, Dr. Liau
⭐️ AACR Advances in Ovarian Cancer Research
⭐️ NWBO to Acquire Advent BioServices
⭐️ Recent Conference
⭐️ DCVax-L Combo PII UCLA
⭐️ DC Combo PII Roswell Park
⭐️ 10-Q Quarterly Report
⭐️ 10-K Annual Report
⭐️ NICE UK 🇬🇧 DCVax-L
⭐️ ASM June 29, 2024
⭐️ Manufacturing Technology
⭐️ NWBO Acquires Flaskworks
⭐️ Roswell Park IP Portfolio
⭐️ TLR3 agonist Ampligen (rintatolimod)
⭐️ Next Generation Dendritic Cell Treatments
⭐️Combo is King!⭐️
AI Fact-Checking
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
